Ultherapy PRIME vs. the original: a new console, the same ultrasound

Ultherapy PRIME is the next generation of Ultherapy. It launched in the United States in September 2024 (Merz Aesthetics 2024) and in Korea in March 2025 (Korea Biomedical Review 2025). It is the device we use, and this article sets out what it shares with the original and what changed.

The ultrasound itself is unchanged

Ultherapy devices use microfocused ultrasound with visualization, or MFU-V. A live ultrasound image shows the tissue layers while points of heat are placed at set depths (Fabi 2015, PMID 25709486). PRIME uses the same handpiece and the same three transducers (1.5, 3.0, and 4.5 mm) as the original, and it delivers the same ultrasound energy (U.S. FDA 510(k) K233996).

By the manufacturer's count, Ultherapy has more than 120 published papers and 56 clinical studies behind it (Merz Aesthetics 2024). Most were done with the previous generation, but since the energy delivery is the same, that evidence carries over to PRIME.

Only the console changed

Inside the console, the changes are the screen, the operating system, and the software. The screen grew from 15 to 18.5 inches, and resolution rose from 1024×768 to 1920×1080. The depth the ultrasound image can show stays at 8 mm (U.S. FDA 510(k) K233996).

The manufacturer also reports a faster processor and a boot time cut nearly in half. It says image noise is lower and the on-screen ultrasound view is twice as wide (Merz Aesthetics 2026). The "20% faster" figure it quotes is device response speed as rated by users in a survey, not treatment time (Merz Aesthetics 2024).

One unblinded survey reports less pain

A survey asked 231 people who had the original and later PRIME to rate pain during treatment. The original scored 5.59 out of 10 and PRIME 2.75. The survey was unblinded and run at a single clinic, and the original's scores came from earlier records (Panithaporn 2025, PMID 40965929). Since the energy, handpiece, and transducers are identical, that gap is hard to attribute to the device itself.

No head-to-head comparison has been published

The only published effectiveness data for PRIME is a single case series of 30 people, sponsored by the manufacturer. At day 90, 86.7% had improved by at least one grade in the jawline and 70% in the neck (Lim 2025, PMID 41282450). No study has yet compared PRIME with the original under the same conditions. It is reasonable to assume the lifting effect is the same. What the evidence so far confirms is an improved console: a bigger screen and faster processing.

For how Ultherapy works and who it suits, see How Ultherapy tightens skin: focused heat at depth, guided by real-time imaging.

References

1. Merz Aesthetics (2024). Merz Aesthetics announces the launch of Ultherapy PRIME platform as the next generation of nonsurgical skin lifting treatments. merzaesthetics.com.
2. Korea Biomedical Review (2025). Merz Aesthetics Korea to launch FDA-approved Ultherapy PRIME in March. koreabiomed.com.
3. Fabi SG (2015). Noninvasive skin tightening: focus on new ultrasound techniques. Clin Cosmet Investig Dermatol. PMID 25709486 (opens in new window).
4. U.S. Food and Drug Administration (2024). 510(k) Summary K233996: Ulthera System (UC-1 Control Unit PRIME). accessdata.fda.gov.
5. Merz Aesthetics (2026). Meet Ultherapy PRIME: physicians. ultherapy.com.
6. Panithaporn D (2025). Pain, erythema, and edema after facial lifting with Ultherapy Prime or Ultherapy Legacy: a survey study. J Cosmet Dermatol. PMID 40965929 (opens in new window).
7. Lim J, et al. (2025). Early experience with Ultherapy Prime in Asia Pacific: a pilot case series. Plast Reconstr Surg Glob Open. PMID 41282450 (opens in new window).